<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440774</url>
  </required_header>
  <id_info>
    <org_study_id>CHIKA01</org_study_id>
    <nct_id>NCT04440774</nct_id>
  </id_info>
  <brief_title>Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.</brief_title>
  <official_title>A Single Centre, Double-blind, Double-dummy Placebo-controlled, Randomised Phase Ib Study to Evaluate the Safety &amp; Immunogenicity of the Candidate Chikungunya Vaccine ChAdOx1 Chik &amp; the Zika Vaccine ChAdOx1 Zika in Healthy Adults in Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise&#xD;
      dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate&#xD;
      ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in&#xD;
      co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan&#xD;
      area of Monterrey (Mexico), will be recruited as participants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1&#xD;
      Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration,&#xD;
      and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12&#xD;
      participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo&#xD;
      administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered&#xD;
      contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika&#xD;
      administered contralaterally. Group 10 will receive placebo in both arms.&#xD;
&#xD;
      Enrolment into this study will be implemented in a step-wise dose escalation manner.&#xD;
      Participants will be first recruited into the vaccination groups at the lowest dose (Groups&#xD;
      1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory&#xD;
      interim clinical safety reviews that participants will be enrolled into the mid dose groups&#xD;
      (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be&#xD;
      enrolled last, after completion and interim clinical safety reviews from the mid dose groups.&#xD;
      Participants allocated to the Placebo group (Group 10) will be evenly distributed across the&#xD;
      dose escalation model.&#xD;
&#xD;
      Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of&#xD;
      the four intervention arms.&#xD;
&#xD;
      The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken&#xD;
      for 6 months after vaccination day&#xD;
&#xD;
      Innovate UK (project number 971557)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of local reactogenicity signs and symptoms</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of solicited systemic reactogenicity signs and symptoms</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of unsolicited adverse events</measure>
    <time_frame>28 days post vaccination</time_frame>
    <description>Occurrence of unsolicited adverse events for 28 days following vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants through standard blood tests (full blood count, liver and kidney function tests)</measure>
    <time_frame>28 days post vaccination</time_frame>
    <description>Change from baseline for safety laboratory measures (haematology and biochemistry blood results)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of serious adverse events during the whole study duration</measure>
    <time_frame>6 months post vaccination</time_frame>
    <description>Occurrence of serious adverse events during the whole study duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via PRNT50</measure>
    <time_frame>6 months post vaccination</time_frame>
    <description>Plaque-reduction neutralisation tests at 50% (PRNT50) against chikungunya and Zika virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via IgG ELISA antibody titres</measure>
    <time_frame>6 months post vaccination</time_frame>
    <description>IgG ELISA antibody titres against proteins of Chikungunya and Zika virus</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Chikungunya</condition>
  <condition>Zika</condition>
  <arm_group>
    <arm_group_label>CHIK low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZIKA low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZIKA mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZIKA high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK ZIKA low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK ZIKA mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK ZIKA high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIK low dose</intervention_name>
    <description>A single dose of 5x10^9 vp ChAdOx1 Chik</description>
    <arm_group_label>CHIK ZIKA low dose</arm_group_label>
    <arm_group_label>CHIK low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIK mid dose</intervention_name>
    <description>A single dose of 2.5x10^10 vp ChAdOx1 Chik</description>
    <arm_group_label>CHIK ZIKA mid dose</arm_group_label>
    <arm_group_label>CHIK mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIK high dose</intervention_name>
    <description>A single dose of 5x10^10 vp ChAdOx1 Chik</description>
    <arm_group_label>CHIK ZIKA high dose</arm_group_label>
    <arm_group_label>CHIK high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZIKA low dose</intervention_name>
    <description>A single dose of 5x10^9 vp ChAdOx1 Zika</description>
    <arm_group_label>CHIK ZIKA low dose</arm_group_label>
    <arm_group_label>ZIKA low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZIKA mid dose</intervention_name>
    <description>A single dose of 2.5x10^10 vp ChAdOx1 Zika</description>
    <arm_group_label>CHIK ZIKA mid dose</arm_group_label>
    <arm_group_label>ZIKA mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZIKA high dose</intervention_name>
    <description>A single dose of 5x10^10 vp ChAdOx1 Zika</description>
    <arm_group_label>CHIK ZIKA high dose</arm_group_label>
    <arm_group_label>ZIKA high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>A single dose of isotonic saline solution (0.9%)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy men aged 18 to 50 (inclusive) years at the time of screening.&#xD;
&#xD;
          2. Healthy women aged 18 to 50 (inclusive) of child-bearing potential who agree to&#xD;
             practice continuous effective contraception (see below) during the study and test&#xD;
             negative for pregnancy on the day(s) of screening and vaccination.&#xD;
&#xD;
          3. Are residents of the metropolitan area of Monterrey, Nuevo León.&#xD;
&#xD;
          4. Provide written informed consent for participation in the study.&#xD;
&#xD;
          5. Able and willing (in the Investigator's opinion) to comply with all study&#xD;
             requirements.&#xD;
&#xD;
          6. Agreement to inform study team of any impending vaccinations either before or during&#xD;
             participation in the study.&#xD;
&#xD;
          7. Agreement to refrain from blood donation during the course of the study.&#xD;
&#xD;
          8. Agreement to refrain from receipt of any alphavirus or flavivirus vaccine throughout&#xD;
             the duration of the study (e.g. investigational or licensed Yellow Fever, Japanese&#xD;
             Encephalitis, Tick Borne Encephalitis or Dengue virus vaccines).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical trial in the 30 days preceding enrolment or during&#xD;
             the study period.&#xD;
&#xD;
          2. Prior receipt of an investigational or licensed vaccine likely to impact on&#xD;
             interpretation of the trial data (e.g. Adenovirus vectored vaccine, Chikungunya virus&#xD;
             vaccine, Zika virus vaccine, Dengue virus vaccine).&#xD;
&#xD;
          3. Prior receipt of any vaccines administered ≤30 days before enrolment and/or planned&#xD;
             during the during the study.&#xD;
&#xD;
          4. Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the planned administration of the vaccine candidate.&#xD;
&#xD;
          5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV&#xD;
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)&#xD;
             immunosuppressant medication within the past 6 months (inhaled and topical steroids&#xD;
             are allowed).&#xD;
&#xD;
          6. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine. Any history of anaphylaxis in relation to vaccination.&#xD;
&#xD;
          7. History of autoimmune disease.&#xD;
&#xD;
          8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
&#xD;
          9. Pregnancy, lactation or willingness/intention to become pregnant during the study.&#xD;
&#xD;
         10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ).&#xD;
&#xD;
         11. History of serious psychiatric condition likely to affect participation in the study&#xD;
&#xD;
         12. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior&#xD;
             history of significant bleeding or bruising following IM injections or venepuncture.&#xD;
&#xD;
         13. Any other serious chronic illness requiring hospital specialist supervision at present&#xD;
             or during the last 6 months.&#xD;
&#xD;
         14. Suspected or known current alcohol abuse. For men, intake greater than 5 drinks on a&#xD;
             single occasion or more than 15 drinks per week; and for women, more than 4 drinks on&#xD;
             a single occasion or more than 8 drinks per week. One drink =14 grams of pure alcohol.&#xD;
&#xD;
         15. Suspected or known injecting drug abuse in the 5 years preceding enrolment.&#xD;
&#xD;
         16. Seropositive for hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
         17. Seropositive for hepatitis C virus (antibodies to HCV).&#xD;
&#xD;
         18. Any clinically significant abnormal finding on screening biochemistry or haematology&#xD;
             blood tests or urinalysis.&#xD;
&#xD;
         19. Has history of chronic or acute severe neurologic condition. Including: Neurologic and&#xD;
             Neuroinflammatory Disorders: ADEM, including site specific variants, Cranial Nerve&#xD;
             Disorders (including paralyses/paresis), GBS (including Miller Fisher Syndrome and&#xD;
             other variants), Immune-mediated Peripheral Neuropathies and Plexopathies, Optic&#xD;
             Neuritis, Multiple Sclerosis, Narcolepsy, Transverse Myelitis, meningitis, or&#xD;
             meningoencephalitis.&#xD;
&#xD;
         20. Any other significant disease, disorder or finding which may significantly increase&#xD;
             the risk to the volunteer because of participation in the study, affect the ability of&#xD;
             the volunteer to participate in the study or impair interpretation of the study data.&#xD;
&#xD;
         21. Seropositivity or cross-reactivity to Chikungunya virus, Zika virus or Dengue virus on&#xD;
             screening tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abiel Homero Mascareñas de los Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario &quot;Dr. José Eleuterio González&quot; Universidad Autónoma de Nuevo León</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo León.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>ChAdOx1</keyword>
  <keyword>Chikungunya</keyword>
  <keyword>Zika</keyword>
  <keyword>Mexico</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

